Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street falls as oil rebounds, Middle East tensions simmer
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Ultragenyx Pharma (RARE) Misses Q1 EPS by 36c
May 6, 2020 5:54 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.05), $0.36 worse than the analyst estimate of ($1.69). Revenue for the quarter came in at $36.31 million versus the consensus estimate of $36.58 million.
The global coronavirus pandemic has created unprecedented challenges for the world at... More
